Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
131.40    1.40 (1.08%)
Bid:
131.20
Ask:
132.60
Spread: 1.40 (1.067%)
Market Cap: £319.85m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director/PDMR Shareholding

13 Nov 2020 17:00

RNS Number : 3174F
PureTech Health PLC
13 November 2020
 

PureTech Health plc (the "Company")

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility or their Connected Persons

 

In connection with the listing of the Company's American Depository Shares ("ADS's") on the Nasdaq Global Market and in order to satisfy Nasdaq listing rules, on 11 November 2020, (i) the Zohar Family Trust I, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to per one ADS and (ii) the Zohar Family Trust II, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to one ADS.

 

The foregoing is a notifiable transaction but does not involve any disposal of such interest. Following this transaction, Ms. Zohar continues to have a direct and indirect interest in 12,197,307 Ordinary Shares, representing approximately 4.3% of the issued share capital of the Company. No Ordinary Shares or ADS's are being sold or disposed of by Ms. Zohar or her related entities in connection with the Nasdaq listing.

 

This notification is made under Article 19 of the Market Abuse Regulation.

 

PDMR DEALING NOTIFICATION

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

The Zohar Family Trust I and The Zohar Family Trust II

2

Reason for the notification

a)

Position/status

Ms. Daphne Zohar, the Chief Executive Officer and a Director, is a Trustee of the above listed Trusts

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of PureTech Health plc

ISIN GB00BY2Z0H74

b)

Nature of the transaction

Conversion by the Zohar Family Trust I of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration and conversion by the Zohar Family Trust II of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Zohar Family Trust I

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

Zohar Family Trust II

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

d)

Aggregated information

-

Aggregated volume

-

Price

 

Price

Aggregate Volume

n/a

n/a

e)

Date of the transaction

11 November 2020

f)

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZXLFFBFLLFBK
Date   Source Headline
28th Oct 201912:07 pmRNSSecond Price Monitoring Extn
28th Oct 201912:02 pmRNSPrice Monitoring Extension
24th Oct 20197:00 amRNSSonde Names Healthcare Tech Exec David Liu as CEO
18th Oct 20194:40 pmRNSSecond Price Monitoring Extn
18th Oct 20194:35 pmRNSPrice Monitoring Extension
4th Oct 20194:40 pmRNSSecond Price Monitoring Extn
4th Oct 20194:35 pmRNSPrice Monitoring Extension
4th Oct 201912:07 pmRNSSecond Price Monitoring Extn
4th Oct 201912:02 pmRNSPrice Monitoring Extension
2nd Oct 20197:00 amRNSMinority Stake Acquisition & PDMR Notification
1st Oct 20194:40 pmRNSSecond Price Monitoring Extn
1st Oct 20194:35 pmRNSPrice Monitoring Extension
1st Oct 20191:15 pmRNSVor Appoints Senior Cell & Gene Therapy Leaders
1st Oct 20197:00 amRNSTotal Voting Rights
23rd Sep 20194:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20194:35 pmRNSPrice Monitoring Extension
23rd Sep 201912:07 pmRNSSecond Price Monitoring Extn
23rd Sep 201912:02 pmRNSPrice Monitoring Extension
23rd Sep 20197:00 amRNSVedanta Expands Series C with $62.1M Total Raised
16th Sep 20194:40 pmRNSSecond Price Monitoring Extn
16th Sep 20194:35 pmRNSPrice Monitoring Extension
9th Sep 201912:07 pmRNSSecond Price Monitoring Extn
9th Sep 201912:02 pmRNSPrice Monitoring Extension
9th Sep 20197:00 amRNSPureTech Announces Board Change
6th Sep 20194:41 pmRNSSecond Price Monitoring Extn
6th Sep 20194:35 pmRNSPrice Monitoring Extension
4th Sep 201912:07 pmRNSSecond Price Monitoring Extn
4th Sep 201912:02 pmRNSPrice Monitoring Extension
27th Aug 20197:00 amRNSPureTech Health plc Half-Year Report
20th Aug 20197:00 amRNSNotice of Results
19th Aug 201912:02 pmRNSPrice Monitoring Extension
14th Aug 20195:30 pmRNSBTG
7th Aug 20191:40 pmRNSVor Names Biotech Vet Robert Ang President & CEO
1st Aug 20197:00 amRNSTotal Voting Rights
31st Jul 20191:40 pmRNSVor Biopharma Adds R&D Leader Bill Lundberg to BOD
17th Jul 20197:00 amRNSPRTC Acquires Clinical Stage Asset for Lymphedema
11th Jul 20197:00 amRNSPotential US Listing of PureTech Health on Nasdaq
9th Jul 20197:00 amRNSPRTC Immuno-Oncology Programme Granted US Patent
3rd Jul 20197:00 amRNSPRTC's Karuna closes IPO, gross proceeds $102.6M
1st Jul 20197:00 amRNSFirst Patient in Vedanta Food Allergy Study
28th Jun 20197:00 amRNSPureTech's Karuna successfully lists on NASDAQ
20th Jun 20197:00 amRNSPureTech Announces New Corporate HQ/Internal Labs
13th Jun 20197:00 amRNSFollica Positive Interim Data & Plans for Pivotal
3rd Jun 20197:00 amRNSPRTC's Karuna Files Public S1 for NASDAQ IPO
30th May 20197:05 amRNSPRTC to Present at Jefferies US Conference
30th May 20197:00 amRNSResult of AGM
29th May 20197:00 amRNSVor Publishes POC Study in Scientific Journal
21st May 20197:00 amRNSVedanta Presents Expanded Data from Successful Ph1
20th May 20197:00 amRNSPromising Gelesis Data in Chronic Constipation
14th May 20197:00 amRNSGelesis & Vedanta Data at Digestive Disease Week

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.